Plus   Neg

Generali Confirms Its 2021 Strategy - Quick Facts

Generali (GDEUF.PK,GE1G) issued an update on the progress of its three-year Generali 2021 strategy, confirming the company's ability to deliver the financial targets by effectively navigating the COVID-19 crisis. Generali said higher contributions from expense reduction and debt optimisation have helped it remain on track to meet its earnings per share target.

Generali stated that the solvency II ratio as of 30th September 2020 was 203%. Financial debt reduction stands at 1.9 billion euros meeting the higher end of the target range for Generali 2021 one year ahead of the plan. The net holding cash flow target of over 7 billion euros is ahead of the Generali 2021 plan.

The Group said it has accelerated business transformation, which is further driving profitability, confirming 1 billion euros in strategic investments. The target of 200 million euros in expense reduction has been secured ahead of plan. In 2021, Generali targets additional 100 million euros in savings raising expense reduction target to 300 million euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.
Follow RTT